October 29, 2024
Intravitreal Injection Articles
October 25, 2024
Gene Therapy Discussion With Drs. Kaiser and Do at AAO
By Peter K. Kaiser, MD, Diana V. Do, MD
October 19, 2024
Eylea HD Data Discussion With Drs. Kaiser and Do at AAO
By Peter K. Kaiser, MD, Diana V. Do, MD
October 18, 2024
Faricimab Effective in Underrepresented DME Patients
By Jim Gallagher, senior managing editor
October 18, 2024
Pegcetacoplan an Effective Treatment for Subfoveal GA
By Jim Gallagher, senior managing editor
October 18, 2024
First Top-Line Data from ELEVATUM on Faricimab Treatment in Underrepresented Minority Populations
By Jeremiah Brown Jr., MS, MD , Michael A. Singer, MD
October 11, 2024
My Approach to Patient Education With Avacincaptad Pegol Treatment
By Ketan G. Laud, MD
October 1, 2024
Results of Recent Trials of Duravyu for Wet AMD
By Carl D. Regillo, MD, FACS
October 1, 2024
A Plan for Biosimilar Integration
By Derek Burns, PharmD, MBA, BCPS, BCSCP, Lisa Lasita, PharmD, MBA
October 1, 2024
An Expanded Role for Faricimab?
By Lauren Pickel, BS, Nirojini Sivachandran, MD, PhD, FRCSC
October 1, 2024
An Expanded Role for Faricimab?
By Lauren Pickel, BS, Nirojini Sivachandran, MD, PhD, FRCSC
October 1, 2024
Clinical Trial Download: The Potential of Optogenetic Therapy
By Yasha Modi, MD , Allen C. Ho, MD, Sulagna Bhattacharya, MBA
October 1, 2024
Anti-VEGF Therapy for Retinopathy of Prematurity
By Vernon S. Volante, BS, Lauren C. Kiryakoza, MD, Hong-Uyen Hua, MD
September 26, 2024
Validating Patient Concerns Regarding Geographic Atrophy and Treatment
By Priya Vakharia, MD
September 5, 2024
Anti-complement Injections for Geographic Atrophy: A Look at the Patient and Provider Experience in my Clinic
By Tanuj Banker, MD
September 1, 2024
The Role of TNF-α Inhibitors in Managing Wet AMD
By Christian Akotoye, MD, Priya Shukla, BS, Rishi P. Singh, MD
September 1, 2024
Choosing Treatment for Primary Vitreoretinal Lymphoma
By Elaine Binkley, MD, Farzad Jamshidi, MD, PhD
September 1, 2024
Intravitreal Chemotherapy for Retinoblastoma
By Vishal R. Raval, MD, Vidhi Bajpai, MS, Arun D. Singh, MD
September 1, 2024
Coding Q&A: Billing for Injectable Drugs
By Brandy H. Sperry, COMT, COE, CPC, CPMA
August 26, 2024
RHONE-X Highlights DME Disease Control and Durability with Faricimab
By Arshad M. Khanani, MD, MA, FASRS, Michael A. Singer, MD
July 29, 2024
36-month Data from the CALM Registry in Uveitis Treatment
By Michael A. Singer, MD
July 25, 2024
Phase 2 LUNA Trial Data Presented at ASRS
July 17, 2024
Supplemental Injection Data From DAVIO 2 Trial of EYP-1901 Presented at ASRS
By Jennifer Ford, senior managing editor
July 17, 2024
Outcomes of Faricimab in DME Study Presented at ASRS
July 10, 2024
FDA Approves Anti-VEGF Biosimilar Drug
July 10, 2024
Vabysmo Prefilled Syringe Receives FDA Approval
July 10, 2024
Faricimab Shows Durable Efficacy and Safety in 2-Year DME Study
July 1, 2024
Study: Time to First Anti-VEGF Injection in Treatment-naïve Wet AMD Patients
By Rochelle Nataloni, contributing writer
July 1, 2024
Understanding Risk Factors for Posterior Capsular Rupture
June 27, 2024
Myth Busting Geographic Atrophy Treatment Options
By Priya Vakharia, MD
June 13, 2024
Patient Selection, Treatment Options, and Beyond With Complement Cascade Inhibitors for GA
By Daniel K. Bennett, MD
June 1, 2024
Upfront: New Efforts to Halt Diabetic Eye Disease
By Peter K. Kaiser, MD
June 1, 2024
Post Hoc Analysis of Phase 2/3 PHOTON Trial Outcomes Presented at ARVO
By Rochelle Nataloni, contributing writer
June 1, 2024
Coding: Medicare Considerations of Compounded Drugs
By Brandy H. Sperry, COMT, COE, CPC, CPMA
June 1, 2024
Controversies in Care: Chlorhexidine as an Alternative to Povidone-iodine for Antisepsis Before Intravitreal Injection
By Michael Colucciello, MD, Jason Fan, MD, PhD, Harry W. Flynn Jr., MD, et al.
June 1, 2024
FDA Approves First Biosimilars to Eylea
By Jim Gallagher, senior managing editor
May 20, 2024
KSI 501: A New Type of Bispecific for the Treatment of Macular Edema
By Mark R. Barakat, MD, Michael A. Singer, MD
May 1, 2024
New Product Applications: Lengthening the Time Between Treatments
By Karen Appold, contributing writer
May 1, 2024
Subspecialty News May 2024
By Rochelle Nataloni, contributing writer
May 1, 2024
Upfront: The Technological Intersection of Aviation and Retina
By Peter K. Kaiser, MD
April 29, 2024
AMARONE Shows Promising Outcomes for a Novel Treatment Pathway in DME and nAMD
By Charles C. Wykoff, MD, PhD, Michael A. Singer, MD
April 25, 2024
How to Optimize the Geographic Atrophy Patient Experience
By Priya Vakharia, MD
April 24, 2024
Exploring Risk of Endophthalmitis With Intravitreal Injections
By Sruthi Arepalli, MD
April 1, 2024
Upfront: Innovations in VEGF Inhibition Delivery
By Peter K. Kaiser, MD
April 1, 2024
Clinical Trial Update April 2024
April 1, 2024
New Product Applications: The First FDA-approved Topical Ocular Anesthetic Debuts
By Karen Appold, contributing writer
April 1, 2024
Improving Durability of Drugs in Wet AMD
By Lucas W. Rowe, MD, Thomas A. Ciulla, MD, MBA
April 1, 2024
Polymeric Technologies for Retinal Drug Delivery
By Xinyi Su, PhD, MMed, FAMS, MBChir, Ivan Seah, MBBS, MBA, MPH
April 1, 2024
Subspecialty News April 2024
By Rochelle Nataloni, contributing writer
April 1, 2024
Tyrosine Kinase Inhibitors for Wet AMD and Diabetic Retinopathy
By Nikhil Das, MD, Katherine E. Talcott, MD
April 1, 2024
Broader VEGF Pathway Inhibition for Wet AMD
By Mark R. Barakat, MD, Mark P. Breazzano, MD
March 26, 2024
Geographic Atrophy: Patient Conversations, Pearls, and Office Workflows
By Rishabh Gupta, MD, Mathew W. MacCumber, MD, PhD, Vivek Chaturvedi, MD
March 8, 2024
Office Workflow Challenges With Anti-complement Therapeutics
By Priya Vakharia, MD
March 1, 2024
Clinical Trial Download: Longer-term Data on New Treatments for Geographic Atrophy
By Yasha Modi, MD , Vaidehi S. Dedania, MD, Talia R. Kaden, MD
March 1, 2024
Considerations in Management of Dry AMD
By Karen W. Jeng-Miller, MD, MPH
March 1, 2024
Subspecialty News March 2024
By Rochelle Nataloni, contributing writer
January 1, 2024
Subspecialty News January/February 2024
By Rochelle Nataloni, contributing writer
January 1, 2024
EyePoint Reports Positive Results of Phase 2 Trial for Investigational AMD Treatment
By Jim Gallagher, senior managing editor
January 1, 2024
CONTROVERSIES IN CARE: Withdrawal of Anti-VEGF Agents in Neovascular AMD
By Michael Colucciello, MD, Anat Loewenstein, MD, MHA, Diana V. Do, MD
January 1, 2024
Therapies for Geographic Atrophy: Safety First
By Hashem Ghoraba, Sumit Sharma, MD
January 1, 2024
Breaking News: 12-month Data for Faricimab for Retinal Vein Occlusion
By Ramin Tadayoni, MD, PhD, Michael A. Singer, MD
January 1, 2024
A Summary of the MERIT Trial: Intravitreal Therapy for Uveitic Macular Edema
By Sruthi Arepalli, MD
November 1, 2023
History, Symptoms, and Management of Coats Disease
By Jay K. Rathinavelu, BSE, Grant A. Justin, MD, Lejla Vajzovic, MD, FASRS
November 1, 2023
SUBSPECIALTY NEWS: Ryzumvi approved, positive gene therapy data, Syfovre receives J code, and more.
By Rochelle Nataloni, contributing writer
November 1, 2023
NEW PRODUCT APPLICATIONS: Drug Slows the Progression of Geographic Atrophy
By Karen Appold, contributing writer
November 1, 2023
Clinical Trial Update November/December 2023
October 1, 2023
A 2023 Update on Treatment Paradigms and Options for Nonproliferative Diabetic Retinopathy
By Saagar A. Pandit, MD, MPH, Michael Klufas, MD
October 1, 2023
The 2023 AAO Retina Product Pavilion
By Peter K. Kaiser, MD
October 1, 2023
SUBSPECIALTY NEWS: Biosimilar FDA application hits roadblock, Apellis provides guidance on Syfovre use, and more.
By Rochelle Nataloni, contributing writer
October 1, 2023
CLINICAL TRIAL DOWNLOAD: Twelve-month Data From a Phase 1 Clinical Trial of OTX-TKI for Wet AMD
By Arshad M. Khanani, MD, MA, FASRS, Paula Pecen, MD, Rabia Gurses Ozden, MD
October 1, 2023
CODING Q&A: Billing Pediatric Retina Cases
By Matthew Baugh, MHA, COT, OCS, OCSR
October 1, 2023
Clinical Trial Update October 2023
October 1, 2023
Clinical Pearls for Newly Approved Treatments for GA
By Aamir A. Aziz, BS, Carl Danzig, MD
September 1, 2023
Managing Treatment Resistance in Neovascular Age-related Macular Degeneration
By Asad F. Durrani, MD, Yoshihiro Yonekawa, MD
September 1, 2023
Glycoimmune Therapy as a Novel Treatment Approach for Geographic Atrophy
By Sophie J. Bakri, MD, MBA, Jeffrey S. Heier, MD, Arshad M. Khanani, MD, MA, FASRS, et al.
September 1, 2023
Bispecific Antibodies in Retina Therapies
By René Rückert, MD, MBA, Gemmy Cheung Chui Ming, FRCOphth, Marion R. Munk, MD, PhD, FEBO
September 1, 2023
The Current Landscape of Anti-VEGF Biosimilars
By Angela S. Li, MD, Sharon Fekrat, MD, FASRS
September 1, 2023
CODING Q&A: Medicare Reimbursement for Discarded Drugs
By Brandy H. Sperry, COMT, COE, CPC, CPMA
September 1, 2023
Clinical Trial Update September 2023
August 22, 2023
Eylea HD 8-mg Injection Approved for Wet AMD, DME, and DR
By Jennifer Ford, senior managing editor
August 7, 2023
Iveric Bio's Izervay Receives FDA Approval as Treatment for Geographic Atrophy
By Jennifer Ford, senior managing editor
July 1, 2023
Managing Drug Shortages in Retina Care
By Roger A. Goldberg, MD, MBA, George N. Magrath, MD, MBA, MS
July 1, 2023
SUBSPECIALTY NEWS: Mydriasis spray approved, laser and imaging devices cleared, new AI technology, and more.
By Rochelle Nataloni, contributing writer
July 1, 2023
CONTROVERSIES IN CARE: Treatment of Geographic Atrophy
By Michael Colucciello, MD, Carl D. Regillo, MD, FACS, Demetrios G. Vavvas, MD, PhD, et al.
July 1, 2023
Clinical Trial Update July/August 2023
June 1, 2023
The Current State of Treatment for Radiation Retinopathy
By Jonathan C. Tsui, MD, Apoorv P. Chebolu, MD, Brian L. Vanderbeek MD, MPH, MSCE
June 1, 2023
Steroid Options for Treatment of Uveitis
By Russel Dinh, Brian K. Do, MD
June 1, 2023
The Retina Product Pavilion 2023
By Peter K. Kaiser, MD
May 1, 2023
Polymers for Retinal Drug Delivery
By Charles D. Blizzard, Dina Akasheh, PhD, Matthew Cheung, PharmD, et al.
May 1, 2023
NEW PRODUCT APPLICATIONS: The First Drug to Treat Geographic Atrophy Debuts
By Karen Appold, contributing writer
May 1, 2023
Clinical Trial Update May 2023
April 1, 2023
Antisepsis for Intravitreal Injections
By Allison B. Hansen, BS, Kamal Kishore, MD, FASRS
April 1, 2023
Current Status of Subretinal Delivery Devices
By Prethy Rao, MD, MPH, Edward Wood, MD, Tamer Mahmoud, MD, PhD
April 1, 2023
UPFRONT: The Beginning of Geographic Atrophy Treatment
By Peter K. Kaiser, MD
April 1, 2023
SUBSPECIALTY NEWS: Early anti-VEGF for DR shows no benefit, developments in gene therapy, research on IRD, and more.
By Rochelle Nataloni, contributing writer
April 1, 2023
Clinical Trial Update April 2023
March 1, 2023
NEW PRODUCT APPLICATIONS: Ranibizumab Biosimilar Offers Lower-price Treatment Option
By Karen Appold, contributing writer
March 1, 2023
Clinical Trial Update March 2023
February 2, 2023
FDA Approves Syfovre as First Treatment for Geographic Atrophy
February 1, 2023
Clinical Trial Update: Special Edition 2023
January 1, 2023
Retinal Fluid Fluctuations in the Treatment of Neovascular AMD
By Veeral S. Sheth, MD, MBA, FACS, Rhianon Reynolds, MD
January 1, 2023
SUBSPECIALTY NEWS: Progress toward GA drug approval, new gene therapy data, and more.
By Rochelle Nataloni, contributing writer
January 1, 2023
CLINICAL TRIAL DOWNLOAD: High-dose Aflibercept for Wet AMD and DME
By Yasha Modi, MD , PAOLO LANZETTA, MD, David Brown, MD
January 1, 2023
CODING Q&A: Intravitreal Medications for Geographic Atrophy
By Suzanne L. Corcoran, COE
January 1, 2023
Clinical Trial Update January/February 2023
November 1, 2022
CONTROVERSIES IN CARE: Examining the Evidence for Macular Atrophy as a Complication of Anti-VEGF Therapy for Wet AMD
By Michael Colucciello, MD
November 1, 2022
NEW PRODUCT APPLICATIONS: The First Surgical System for Subretinal Injections Debuts
By Karen Appold, contributing writer
October 1, 2022
CODING Q&A: Reimbursement Rules for Intravitreal Injections
By Suzanne L. Corcoran, COE
July 1, 2022
The Importance of Early Referral for Neovascular AMD
By Miguel A. Busquets, MD
July 1, 2022
Potential Implications of Silicone Oil From Syringes
By Gustavo B. Melo, MD, PhD, FASRS
July 1, 2022
UPFRONT: Retina Drug Shortages
By Peter K. Kaiser, MD
June 1, 2022
Intravitreal Methotrexate for the Treatment and Prevention of Proliferative Vitreoretinopathy
By Priya Vakharia, MD
June 1, 2022
SUBSPECIALTY NEWS: Geographic atrophy quality-of-life survey, Xipere launch, ophthalmic bevacizumab FDA application, and more.
By Rochelle Nataloni, contributing writer
June 1, 2022
NEW PRODUCT APPLICATIONS: Xipere Suprachoroidal Injection for Uveitis
By ANDREA BONNER, CONTRIBUTING EDITOR
May 1, 2022
Combination Laser and Anti-VEGF for Retinal Ischemic Areas
By Nitish Mehta, MD, Yasha Modi, MD
May 1, 2022
CODING Q&A: Avoiding Audit Traps for Intravitreal Injections
By Suzanne L. Corcoran, COE
April 1, 2022
Complications of Intravitreal Injections
By Efrat Fleissig, MD, Anat Loewenstein, MD, MHA
April 1, 2022
Treating AMD at the Intermediate Level
By Carla Danese, MD, PAOLO LANZETTA, MD
April 1, 2022
The Current Landscape of Intravitreal Treatments for Neovascular AMD
By Matias Iglicki, MD, Anat Loewenstein, MD, MHA, Dinah Zur, MD
April 1, 2022
UPFRONT: Medical Therapy in a Time of War
By Peter K. Kaiser, MD
March 1, 2022
Intraocular Inflammation Associated With Current and Prospective Therapies for Patients With Wet AMD
By Andreas M. Wingert, Jayanth Sridhar, MD
February 1, 2022
Faricimab Approved by the FDA for Wet AMD and DME
By Rochelle Nataloni, contributing writer
January 1, 2022
SUBSPECIALTY NEWS: Real-world Iluvien data, advances to program for choroidal melanoma treatment, results for at-home OCT, and more.
By Rochelle Nataloni, contributing writer
Advertisement
Recommendations
Advertisement